Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK ACCESSWIRE
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on MRNA
    Moderna to Present at Upcoming Conferences in September 2025
    7:12a ET August 21 '25 ACCESSWIRE

    CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences:

    Morgan Stanley's 23rd Annual Global Healthcare Conference, on Monday, September 8th at 10:00am ET

    Bernstein Insights: Healthcare Leaders and Disruptors, on Thursday, September 25th at 10:30am ET

    A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website.

    investors.modernatx.com.

    A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.

    Aboutâ?¯Moderna

    Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

    Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

    Media Contacts

    Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations617-209-5834Lavina.Talukdar@modernatx.com

    SOURCE: Moderna, Inc.

    View the original press release on ACCESS Newswire

    COMTEX_468200973/2457/2025-08-21T07:12:04

    Moderna Announces mNEXSPIKE Generates Strong Immune Response Against ...
    7:12a ET September 23 '25 ACCESSWIRE
    Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Can...
    3:22p ET September 19 '25 ACCESSWIRE
    Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Gen...
    6:12a ET September 16 '25 ACCESSWIRE
    Moderna Announces Data to be Presented at the 2025 International Cong...
    7:06a ET September 2 '25 ACCESSWIRE
    Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targ...
    2:02p ET August 27 '25 ACCESSWIRE
    Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine ...
    9:26a ET August 22 '25 ACCESSWIRE
    Moderna to Present at Upcoming Conferences in September 2025
    7:12a ET August 21 '25 ACCESSWIRE
    Moderna Reports Second Quarter 2025 Financial Results and Provides Bu...
    7:12a ET August 1 '25 ACCESSWIRE
    UK Court of Appeal Confirms Moderna's EP'949 Patent is Valid and Infr...
    6:12a ET August 1 '25 ACCESSWIRE
    Moderna Receives European Commission Approval for Updated COVID-19 Va...
    4:12p ET July 30 '25 ACCESSWIRE

    Market data provided by News provided by